Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Standard BioTools Inc. on the transaction, and Fenwick & West advised SomaLogic, Inc. Standard BioTools Inc. (Nasdaq: LAB) and SomaLogic (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing Pacific Biosciences, and Fenwick & West is representing Apton Biosystems in the transaction. 8Pacific Biosciences of California (NASDAQ: PACB) (PacBio) announced...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Recludix Pharma in the deal. Recludix Pharma announced that it has entered into a strategic collaboration with Sanofi (NASDAQ: SNY) to develop and...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...
You must be a Standard 1 Year member to access this content.
Fenwick advised Shockwave Medical, Inc. on the deal. Shockwave Medical, Inc. (NASDAQ: SWAV), a medical device company focused on the development of Intravascular Lithotripsy (IVL) to...
You must be a Standard 1 Year member to access this content.
Fenwick represented Belharra Therapeutics on the deal. Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, announced its multi-year collaboration with...
You must be a Standard 1 Year member to access this content.
Fenwick represented Sutro Biopharma on the deal. Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), announced its option grant...
You must be a Standard 1 Year member to access this content.
Fenwick represented SyntheX on the deal. SyntheX, a biotechnology company innovating next-generation functional drug discovery engines, announced its research collaboration and license agreement with Bristol Myers...
You must be a Standard 1 Year member to access this content.
Fenwick represented Scribe Therapeutics on the deal. Scribe Therapeutics, a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, announced its strategic collaboration and...
You must be a Standard 1 Year member to access this content.
Fenwick represented Sutro Biopharma, Inc. on the deal. Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company, announced its strategic collaboration and licensing agreement with Astellas Pharma...
You must be a Standard 1 Year member to access this content.
Fenwick advised Deepcell on the deal. Deepcell, a life science company pioneering AI-powered single cell classification and isolation for basic and translational research, announced its $73 million...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Calm on the deal while O’Melveny represented Ripple Health Group. Calm, a mental wellness brand with an app for sleep, meditation and...
You must be a Standard 1 Year member to access this content.
